Stemline Therapeutics Becomes Oversold (STML)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Tuesday, shares of Stemline Therapeutics Inc ( STML) entered into oversold territory, hitting an RSI reading of 29.8, after changing hands as low as $13.20 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 47.7. A bullish investor could look at STML's 29.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of STML shares:

START SLIDESHOW:
Find out what 9 other oversold stocks you need to know about »

Stemline Therapeutics Inc 1 Year Performance Chart

Looking at the chart above, STML's low point in its 52 week range is $10.50 per share, with $18.94 as the 52 week high point — that compares with a last trade of $13.37.

If you liked this article you might like

These 5 Stocks Under $10 Could Explode Up Soon

Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money

Trial Patient Dies From a Stemline SL-401 Side Effect

Trade These 7 Stocks Under $10 for Huge Profits

Insider Trading Alert - STML, ARCC And PATK Traded By Insiders